Advertisement
Australia markets close in 2 hours 7 minutes
  • ALL ORDS

    7,795.90
    -103.00 (-1.30%)
     
  • ASX 200

    7,546.10
    -96.00 (-1.26%)
     
  • AUD/USD

    0.6400
    -0.0025 (-0.39%)
     
  • OIL

    84.82
    +2.09 (+2.53%)
     
  • GOLD

    2,406.00
    +8.00 (+0.33%)
     
  • Bitcoin AUD

    96,821.80
    -121.93 (-0.13%)
     
  • CMC Crypto 200

    1,274.92
    +389.38 (+42.23%)
     
  • AUD/EUR

    0.6012
    -0.0018 (-0.30%)
     
  • AUD/NZD

    1.0874
    -0.0001 (-0.01%)
     
  • NZX 50

    11,746.64
    -89.40 (-0.76%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,180.12
    -205.75 (-1.26%)
     
  • NIKKEI 225

    37,167.11
    -912.59 (-2.40%)
     

2 Growth Stocks That Could Double in 2023

2 Growth Stocks That Could Double in 2023

Investing in biotech companies, especially relatively small ones, can be a double-edged sword. With that in mind, let's look at two gene-editing-focused biotechs that could perform substantially better next year: CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE). Right now, CRISPR Therapeutics is a clinical-stage biotech.